What is Arvinas?
Founded in 2013 and headquartered in New Haven, Connecticut, Arvinas is at the forefront of developing novel therapies that degrade disease-causing proteins. The company's innovative approach targets debilitating and life-threatening diseases, aiming to provide new treatment options for patients. Arvinas operates within the clinical-stage biopharmaceutical sector, a field characterized by rigorous scientific research, extensive clinical trials, and a high potential for transformative medical advancements. The company's focus on protein degradation represents a significant area of therapeutic innovation, positioning it as a key player in the future of medicine.
How much funding has Arvinas raised?
Arvinas has raised a total of $234.8M across 5 funding rounds:
Series A
$15M
Corporate Investment
$3.3M
Series B
$41.6M
Series C
$55M
Stock Offering
$120M
Series A (2013): $15M with participation from Connecticut Innovations, Elm Street Ventures, Canaan Partners, and 5AM Ventures
Corporate Investment (2013): $3.3M led by Connecticut Department of Economic and Community Development and Connecticut Innovations
Series B (2015): $41.6M supported by Canaan Partners, 5AM Ventures, OrbiMed, New Leaf Venture Partners, and RA Capital Management
Series C (2018): $55M featuring New Leaf Venture Partners, Sirona Capital, RA Capital Management, Hillhouse Capital, Nextech Invest, Canaan Partners, 5AM Ventures, OrbiMed, and Deerfield
Stock Issuance/Offering (2018): $120M backed by Undisclosed
Key Investors in Arvinas
Connecticut Innovations
Connecticut Innovations (ctinnovations.com) is Connecticuts strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health. With offices in the U.S. and Israel and billions of dollars under management, Canaan has funded hundreds of startups and supported dozens of IPOs and acquisitions.
5AM Ventures
Five AM Ventures is a life science focused venture capital firm that backs early stage biotech and health care innovators, partnering closely with founders to shape companies, fund rigorous science and help bring new therapies and technologies to patients.
What's next for Arvinas?
The recent major strategic investment signals Arvinas's progression into a scaling phase, likely focused on advancing its clinical pipeline and expanding its commercialization efforts. This capital infusion will be critical for navigating the complexities of late-stage clinical development, regulatory approvals, and potential market entry. Arvinas's strategic focus on protein degradation therapies suggests a forward-looking approach to drug discovery, aiming to address unmet medical needs across various disease areas. Continued investment and strategic partnerships will be pivotal for the company's long-term growth and its ability to bring life-changing treatments to patients.
See full Arvinas company page
